Supplementary Data from A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S1A: Phenotypic analysis of surface markers on human DCs transfected with MVA-BN-CV301 and FPV-CV301 vectors Supplementary Table S1B: Activation of CEA- and MUC1-specific T-cells by MVA-BN-CV301 and FPV-CV301 Supplementary Table S2: Number of patients reporting adverse events possibly, probably or definitely attributed to CV301 (n=202 events in total) Supplementary Table S3: Development of CEA- and MUC1-specific T-cells by BN-CV301 Supplementary Figure S1: KRAS specific responses assessed in 3 patients preâ€' and postâ€'BN- CV301 vaccine
Authors: Margaret E. Gatti-Mays, Julius Strauss, Renee N. Donahue, Claudia Palena, Jaydira Del Rivero, Jason M. Redman, Ravi A. Madan, Jennifer L. Marté, Lisa M. Cordes, Elizabeth Lamping, Alanvin Orpia, Andrea Burmeister, Eva Wagner, Cesar Pico Navarro, Christopher R. Heery, Jeffrey Schlom, James L. Gulley
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361935942